Litigation

• Byetta Thyroid Cancer Lawsuit Centralization Request Filed with JPML
• MDL Arguments Over Centralization of Lipitor Diabetes Cases Postponed
• Top DOJ Atty Outline Pharma Fraud Enforcement (subscription required)
• Possible Sanctions for Takeda in Actos Bladder Cancer MDL (subscription required)
• Hydroxycut False Ad Claims Must Be Clarified, Judge Says (subscription required)
• GNC Hit with Suit Claiming Diet Pills Led to Liver Damage (subscription required)
• J&J Beats $258M Risperdal Verdict in Split La. High Court (subscription required)
• Calif. Court Reverses Preemption of Medtronic Injury Suit (subscription required)
• 4^th Circ. Tosses Generic-Drug Injury Appeal Against Pliva (subscription required)
• Master Complaint for Stryker Rejuvenate Hip Lawsuits Approved
• Zimmer NexGen Knee Lawsuits to be Selected for First Case Picks in MDL
• DePuy Just Can’t Shake Those Hip Replacement Lawsuits (subscription required)
•  Actos Bellwether Trial Set to Begin in MDL
• 3^rd Circ. To Review Venue Ruling in GSK Birth Defects Cast (subscription required)
• 7^th Circ. Reverses Boehringer Depo Order in Pradaxa MDL (subscription required)
• St. Jude Can’t Shake Defective Defibrillator Suits (subscription required)
• 6^th Circ. Won’t Rehear Generic-Reglan Injury Claims (subscription required)
• Pradaxa Bellwether Lawsuits Selected for First Trial Dates in MDL
• Byetta, Januvia Litigation Being Coordinated Between Federal, State Court
• Pa. Pharma Ruling Opens New Front in Mass Tort Battles (subscription required)

Regulatory

• What Attorneys Should Know about FDA’s MedWatch Data (subscription required)
• FDA Scolds Texas Drugmaker Over STD Product Promos (subscription required)
• Premarket Approval (PMA) Summary Review Memos for 180-Day Design Changes
• “Natural” Labeling Row Remains FDA’s Domain Gruma Says (subscription required)
• J&J Urges FDA Deference In Baby Wash False Ad Action (subscription required)
• What’s In The Wash? FDA Rules On Antibacterial Soaps (subscription required)
• Improving the Quality of Abbreviated New Drug Application Submissions to the Food and Drug Administration, Establishment of a Public Docket
• Another Ranbaxy Drug Plant Fails FDA Test
• GOP Lawmakers Rip FDA’s Generic-Drug Labeling Overhaul (subscription required)

For a look at last week’s life science headlines, click here.